Le Lézard
Classified in: Health
Subject: PER

Dr. Jeff Balser Named to Varian Board of Directors


PALO ALTO, Calif., Sept. 12, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced that Jeffrey R. Balser, MD, PhD, president and chief executive officer at Vanderbilt University Medical Center and dean of Vanderbilt University School of Medicine, has been appointed to the Varian Board of Directors, effective October 1, 2018.

"We are very pleased that Jeff Balser has joined the Varian board," said R. Andrew Eckert, chairman of Varian's Board of Directors. "Jeff brings to Varian a diverse and proven skill set as a physician, scientist and businessman. We look forward to his contributions in assisting Varian's transformation from the leader in radiation therapy to the leader in cancer care solutions."

"Varian has a well-earned reputation as a strong mission-driven company developing and delivering innovative cancer care solutions," said Dr. Balser. "I look forward to working with my fellow Board members and the Varian team to continue the company's growth efforts in creating a world without the fear of cancer."

Dr. Balser, 56, has served as the president and CEO of Vanderbilt University Medical Center since 2016 and the dean of Vanderbilt University School of Medicine since 2008. During this time, he has led the Medical Center through a period of increased service volume with major inpatient expansions of the children's hospital and the adult critical care areas. Dr. Balser earned his medical and PhD degrees from Vanderbilt University and completed his residency and fellowship training at The Johns Hopkins Hospital. Additionally, he earned a Bachelor of Science degree in Engineering from Tulane University.

About Varian
Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Press Contact
Mark Plungy
Director, Public Relations
+1 (650) 424-5630
[email protected]

Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
[email protected]

 

SOURCE Varian


These press releases may also interest you

at 20:25
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...



News published on and distributed by: